查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1608028

人類絨毛膜促性腺激素分泌市場：按產品、治療領域和最終用戶 - 2025-2030 年全球預測

Human Chorionic Gonadotropin Market by Product (Naturally Extracted, Recombinant), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermia Treatment), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，人類絨毛膜促性腺激素分泌市值為12.7億美元，預計2024年將達到13.7億美元，複合年成長率為7.53%，到2030年將達到21.1億美元。

人類絨毛膜促性腺激素分泌（HCG）是懷孕期間胎盤產生的一種激素，對胎兒發育起著重要作用。在市場研究中，觀察到 HCG 在不孕症治療、體重管理治療和妊娠檢測診斷應用方面具有商業性應用。對 HCG 的需求主要在於透過其在體外受精 (IVF) 等輔助生殖技術 (ART) 中的使用來協助生殖健康。 HCG 的醫療用途不僅限於不孕症治療，而且由於它存在於某些類型的癌症中，因此也在腫瘤檢測和管理等領域進行研究。最終用途範圍包括生育診所、實驗室、製藥公司和診斷中心。

主要市場統計
基準年[2023] 12.7億美元
預測年份 [2024] 13.7億美元
預測年份 [2030] 21.1億美元
複合年成長率（%） 7.53%

影響 HCG 市場的主要成長要素包括不孕症盛行率的增加、生殖健康意識的增強以及生物技術的進步促進創新治療方案。此外，對快速診斷試劑套件的需求不斷成長也推動了市場的發展。擴大 HCG 在腫瘤學中的應用範圍並開發體重管理製劑可能為治療方法開發鋪平道路。然而，監管障礙、道德考量和不孕症治療的高成本等挑戰可能會構成重大限制並抑制市場成長。社會文化因素，包括與不孕症治療相關的恥辱，也可能阻礙市場採用。

對於技術創新和業務成長，專注於精準醫療和HCG生化途徑的研究並擴大其治療應用可能會增強市場活力。此外，可以透過投資具有成本效益的治療方法以及在生物技術公司、研究機構和醫療保健提供者之間建立強大的合作網路來擴大市場滲透率。 HCG 市場的本質是動態的，基因研究和生物製造的創新為演化提供了潛在的催化劑。了解消費者需求、利用新的生物技術和促進道德透明度可以引導市場相關人員實現永續成長和競爭優勢。

市場動態：揭示快速發展的人類絨毛膜促性腺激素分泌市場的關鍵市場洞察

供需的動態交互作用正在改變人類絨毛膜促性腺激素分泌市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 不孕人口增加
    • 加大對生育診所發展的投資
    • 提高不孕症治療意識
  • 市場限制因素
    • 人類絨毛膜促性腺激素分泌治療的高成本
  • 市場機會
    • 基因重組技術的進展
    • 促性腺激素分泌療法在醫療保健領域的出現
  • 市場挑戰
    • 人類絨毛膜促性腺激素分泌治療可能產生的副作用

波特的五力：駕馭人類絨毛膜促性腺激素分泌市場的策略工具

波特的五力框架是了解人類絨毛膜促性腺激素分泌市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解對人類絨毛膜促性腺激素分泌市場的外部影響

外部宏觀環境因素在塑造人類絨毛膜促性腺激素分泌市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解人類絨毛膜促性腺激素分泌市場的競爭格局

對人類絨毛膜促性腺激素分泌市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣人類絨毛膜促性腺激素分泌市場供應商的績效評估

FPNV 定位矩陣是評估人類絨毛膜促性腺激素分泌市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製人類絨毛膜促性腺激素分泌市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對人類絨毛膜促性腺激素分泌市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 不孕不育人口增加
      • 加大生育診所建設投入
      • 提高不孕症治療意識
    • 抑制因素
      • 人類絨毛膜促性腺激素分泌治療的高成本
    • 機會
      • 重組技術的進展
      • 促性腺激素分泌療法在醫療保健領域的出現
    • 任務
      • 人類絨毛膜促性腺激素分泌治療可能產生的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章人類絨毛膜促性腺激素分泌市場：依產品

  • 自然提取
  • 重組

第7章依治療領域分類的人類絨毛膜促性腺激素分泌市場

  • 女性不孕症治療
  • 男性性腺功能低下症
  • 少精症的治療

第8章 人類絨毛膜促性腺激素分泌市場：依最終用戶分類

  • 不孕不育治療診所
  • 調查機構

第9章北美和南美人絨毛膜促性腺激素分泌市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區人類絨毛膜促性腺激素分泌市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲人絨毛膜促性腺激素分泌市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Biocare Medical, LLC
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Ferring BV
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • Kamia Biomedical Company
  • Lee Biosolutions, Inc.
  • Life Medicare & Biotech Private Limited
  • Livzon Pharmaceutical Group Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Prospec-Tany Technogene Ltd.
  • Qingdao kangyuan Biopharmaceutical Group Co., Ltd.
  • Sanzyme（P）Ltd.
  • Scripps Laboratories, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Sunrise International Labs Ltd.
Product Code: MRR-6108DAA288C5

The Human Chorionic Gonadotropin Market was valued at USD 1.27 billion in 2023, expected to reach USD 1.37 billion in 2024, and is projected to grow at a CAGR of 7.53%, to USD 2.11 billion by 2030.

Human Chorionic Gonadotropin (HCG) is a hormone produced during pregnancy by the placenta, playing a critical role in fetal development. In the market research context, HCG is observed for its commercial applications in fertility treatments, weight management therapies, and its diagnostic use in pregnancy tests. The necessity for HCG hinges on its application in assisting reproductive health, primarily through its use in assisted reproductive technologies (ART) like in-vitro fertilization (IVF). Its medical applications extend beyond fertility, as it's being researched in areas such as tumor detection and management due to its presence in certain cancer types. The end-use scope covers fertility clinics, research laboratories, pharmaceutical companies, and diagnostic centers.

KEY MARKET STATISTICS
Base Year [2023] USD 1.27 billion
Estimated Year [2024] USD 1.37 billion
Forecast Year [2030] USD 2.11 billion
CAGR (%) 7.53%

Key growth factors influencing the HCG market include the increasing prevalence of infertility, rising awareness regarding reproductive health, and advancements in biotechnology facilitating innovative treatment options. Additionally, the market is propelled by the growing demand for rapid diagnostic kits. A potential opportunity lies in expanding the scope of HCG applications in oncology and developing its formulations to address weight management, opening streams for therapeutic developments. However, challenges such as regulatory hurdles, ethical considerations, and the high cost of fertility treatments pose significant limitations, potentially restraining market growth. Even socio-cultural factors, including the stigma attached to fertility treatments, could dampen market adoption.

For innovation and business growth, focusing on research in precision medicine and the biochemical pathways of HCG to broaden its therapeutic applications could enhance market viability. Moreover, investing in cost-effective treatment methodologies and establishing strong collaborative networks among biotech firms, research institutes, and healthcare providers can extend market penetration. The nature of the HCG market is dynamic, with innovations in genetic research and biomanufacturing catalyzing potential evolution. Understanding consumer needs, leveraging emerging biotechnologies, and fostering ethical transparency can guide market actors towards sustainable growth and competitive advantage.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Chorionic Gonadotropin Market

The Human Chorionic Gonadotropin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidents of infertility among populations
    • Growing investments in the development of fertility clinics
    • Increasing awareness of fertility treatments
  • Market Restraints
    • High cost associated with human chorionic gonadotropin therapy
  • Market Opportunities
    • Advancements in recombinant technology
    • Emergence of gonadotropin therapy in the healthcare sector
  • Market Challenges
    • Possible side effects of human chorionic gonadotropin therapy

Porter's Five Forces: A Strategic Tool for Navigating the Human Chorionic Gonadotropin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Chorionic Gonadotropin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Chorionic Gonadotropin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Chorionic Gonadotropin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Chorionic Gonadotropin Market

A detailed market share analysis in the Human Chorionic Gonadotropin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Chorionic Gonadotropin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Chorionic Gonadotropin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Chorionic Gonadotropin Market

A strategic analysis of the Human Chorionic Gonadotropin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Chorionic Gonadotropin Market, highlighting leading vendors and their innovative profiles. These include Biocare Medical, LLC, Bristol Myers Squibb Company, Cipla Limited, Ferring B.V., Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Kamia Biomedical Company, Lee Biosolutions, Inc., Life Medicare & Biotech Private Limited, Livzon Pharmaceutical Group Inc., Lupin Limited, Merck & Co., Inc., Prospec-Tany Technogene Ltd., Qingdao kangyuan Biopharmaceutical Group Co., Ltd., Sanzyme ( P ) Ltd., Scripps Laboratories, Inc., Sun Pharmaceutical Industries Ltd., and Sunrise International Labs Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Chorionic Gonadotropin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Naturally Extracted and Recombinant.
  • Based on Therapeutic Area, market is studied across Female Infertility Treatment, Male Hypogonadism, and Oligospermia Treatment.
  • Based on End-User, market is studied across Fertility Clinics and Research Institutions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidents of infertility among populations
      • 5.1.1.2. Growing investments in the development of fertility clinics
      • 5.1.1.3. Increasing awareness of fertility treatments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with human chorionic gonadotropin therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in recombinant technology
      • 5.1.3.2. Emergence of gonadotropin therapy in the healthcare sector
    • 5.1.4. Challenges
      • 5.1.4.1. Possible side effects of human chorionic gonadotropin therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Human Chorionic Gonadotropin Market, by Product

  • 6.1. Introduction
  • 6.2. Naturally Extracted
  • 6.3. Recombinant

7. Human Chorionic Gonadotropin Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Female Infertility Treatment
  • 7.3. Male Hypogonadism
  • 7.4. Oligospermia Treatment

8. Human Chorionic Gonadotropin Market, by End-User

  • 8.1. Introduction
  • 8.2. Fertility Clinics
  • 8.3. Research Institutions

9. Americas Human Chorionic Gonadotropin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Human Chorionic Gonadotropin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Human Chorionic Gonadotropin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Biocare Medical, LLC
  • 2. Bristol Myers Squibb Company
  • 3. Cipla Limited
  • 4. Ferring B.V.
  • 5. Fresenius Kabi AG
  • 6. Intas Pharmaceuticals Ltd.
  • 7. Kamia Biomedical Company
  • 8. Lee Biosolutions, Inc.
  • 9. Life Medicare & Biotech Private Limited
  • 10. Livzon Pharmaceutical Group Inc.
  • 11. Lupin Limited
  • 12. Merck & Co., Inc.
  • 13. Prospec-Tany Technogene Ltd.
  • 14. Qingdao kangyuan Biopharmaceutical Group Co., Ltd.
  • 15. Sanzyme ( P ) Ltd.
  • 16. Scripps Laboratories, Inc.
  • 17. Sun Pharmaceutical Industries Ltd.
  • 18. Sunrise International Labs Ltd.

LIST OF FIGURES

  • FIGURE 1. HUMAN CHORIONIC GONADOTROPIN MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HUMAN CHORIONIC GONADOTROPIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HUMAN CHORIONIC GONADOTROPIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN CHORIONIC GONADOTROPIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN CHORIONIC GONADOTROPIN MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY NATURALLY EXTRACTED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FEMALE INFERTILITY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY MALE HYPOGONADISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY OLIGOSPERMIA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. HUMAN CHORIONIC GONADOTROPIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. HUMAN CHORIONIC GONADOTROPIN MARKET, FPNV POSITIONING MATRIX, 2023